Navigation Links
ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Date:8/19/2007

atment of metastatic colorectal cancer across the U.S. and in Europe. Patients are randomized to two arms containing either CoFactor or leucovorin, each in combination with the widely used cancer chemotherapy regimen of 5-FU and bevacizumab (Avastin(R)). The primary endpoint for the study is progression-free survival. Secondary endpoints include response rate, overall survival and incidence and severity of adverse events. The protocol and planned analysis were developed with and accepted by the FDA under a Special Protocol Assessment.

About ANX-510, or CoFactor

CoFactor is a folate-based biomodulator drug designed to replace leucovorin as the preferred method to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapeutic agent 5-FU. In comparison to leucovorin, CoFactor creates more stable binding of the active form of 5-FU to the target enzyme, thymidylate synthase (TS). CoFactor bypasses the metabolic pathway required by leucovorin to deliver the active form of folate, allowing 5-FU to work more effectively. CoFactor is in Phase 3 and Phase 2b clinical trials for the treatment of metastatic colorectal cancer, as well as in a Phase 2 clinical trial for the treatment of advanced breast cancer.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases. The Company seeks to improve the performance and safety of existing treatments by addressing significant problems, such as drug metabolism and bioavailability, excessive toxicity and treatment resistance. More information can be found on ADVENTRX's web site at http://www.adventrx.com.

Forward-Looking Statements

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3

Related medicine technology :

1. ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic Testing of ANX-514 (Docetaxel Emulsion)
2. Adventrx Announces Positive Data From Multidrug Therapy With CoFactor
3. ADVENTRX to Present CoFactor Multiagent Therapy Data at AACR Annual Meeting
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Sygnis Pharma AG announces date for presentation of clinical results
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)...  Cardica, Inc. (Nasdaq: CRDC ) today announced ... quarter and year ended June 30, 2014, on Thursday, August ... a conference call at 4:30 p.m. Eastern Time to discuss ... business. Conference Call Details To access the live ... Time via phone, please dial 866-953-6859 from the ...
(Date:7/23/2014)... 2014  MiMedx Group, Inc.  (NASDAQ: ... of patent-protected regenerative biomaterials and bioimplants processed from ... its initial Investigational New Drug ("IND") application with ... The IND submission, which was filed yesterday, ... for certain indications of its micronized allografts towards ...
(Date:7/23/2014)... 23, 2014  ACON Equity Partners III, L.P., a ... ("ACON") announced it has completed the purchase of Injured ... Group and Parthenon Capital Partners. IWP is a leading ... Compensation, Automobile Personal Injury Protection and Personal Injury pharmacy ... As part of this transaction, ACON ...
Breaking Medicine Technology:Cardica to Announce Fiscal 2014 Fourth Quarter and Full Year Financial Results on Thursday, August 7, 2014 2MiMedx Files Its Initial Investigational New Drug Application 2MiMedx Files Its Initial Investigational New Drug Application 3ACON Investments Acquires Injured Workers Pharmacy 2ACON Investments Acquires Injured Workers Pharmacy 3
... from EAP in 2007, RICHMOND, Va., Jan. ... follow-on biologics and biopharmaceuticals, today,provided an update on ... the treatment of Amyotrophic Lateral Sclerosis (ALS). Since ... physicians and approximately 70 subjects,have been enrolled into ...
... Kind in US, Finds Allergy Immunotherapy ... Beneficial Even When Treatment Not Completed, MOSS ... health economics and outcomes research, today announced,findings of a ... benefits to children and significantly reduces health,care costs, even ...
Cached Medicine Technology:Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis 2Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis 3Study Says Allergy Shots Help Children, Reduce Health Care Costs 2Study Says Allergy Shots Help Children, Reduce Health Care Costs 3
(Date:7/23/2014)... (PRWEB) July 23, 2014 According to ... Market by Form Factor (Integrated Circuit IP, SOC IP), ... DSP), Application, Geography and Verification IP - Forecast & ... market is expected to grow at a CAGR of ... in 2020. , Browse more than 76 market data ...
(Date:7/23/2014)... The Centers for Disease Control and Prevention ... from 2010 to 2012. Formerly known as “the nation’s ... access to some of the strongest opiates, such as Oxycontin, ... enforcement launched an initiative to crack down on these rampant ... 65 that existed in the state just a few years ...
(Date:7/23/2014)... Asian women has identified three genetic changes linked to ... by Vanderbilt University investigators, was published online July 20 ... is one of the most common malignancies among women ... the disease have focused on women of European ancestry. ... exposures between East Asian women and those of European ...
(Date:7/23/2014)... 2014 The Circuelle Foundation compiled ... institutions uncovering the importance of breast self-exams (BSE). ... for breast self-exams is contradictory and can be ... for keeping this healthy ritual. , “Women are ... significance of breast self-exams and becoming breast aware,” ...
(Date:7/23/2014)... 23, 2014 Five years ago, when the ... were few options for babies diagnosed with a medical condition ... across the country for innovative fetal therapies. Since then, nearly ... to care for their babies in the womb, and the ... , “A number of the babies we see are ...
Breaking Medicine News(10 mins):Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 5Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 6Health News:Florida’s Crackdown on Pill Mills Has Led to Rise in Popularity of Synthetic Drugs; Suncoast Rehab Educates on Dangers of These Drugs in Adolescents 2Health News:Florida’s Crackdown on Pill Mills Has Led to Rise in Popularity of Synthetic Drugs; Suncoast Rehab Educates on Dangers of These Drugs in Adolescents 3Health News:Florida’s Crackdown on Pill Mills Has Led to Rise in Popularity of Synthetic Drugs; Suncoast Rehab Educates on Dangers of These Drugs in Adolescents 4Health News:Vanderbilt-led study identifies genes linked to breast cancer in East Asian women 2Health News:Historical and Current Research Points to Importance of Breast Self-Exams 2Health News:St. Louis Fetal Care Institute Marks Five Years of Life Changing Care and Fetal Surgery 2
... FairWarning(R) announces 2007 achievements and foundation for ... 29 Today, FairWarning(R),announced 2007 company achievements ... further,the company,s position as the leading provider ... http://www.newscom.com/cgi-bin/prnh/20080128/FAIRWARNINGLOGO ), 2007 Growth ...
... DENVER, Jan. 29 HealthAware, a leading supplier ... launch of,WeightAware, the newest disease module in its ... with obesity and,arthritis. The program targets only those ... within 12 months., WeightAware is an extension ...
... name, company introduces new out-of-the-box proactive, ... ST. PETERSBURG, Fla., Jan. 29 EpicTide ... FairWarning(R). The company,s corporate,structure and mission remains unchanged. ... supplier of cross-platform privacy auditing,solutions for Electronic Health ...
... reported results include 22 percent sales growth and EPS of $.78, - Q4 pro forma adjusted results ... ... both sales and ... EPS, INDIANAPOLIS, Jan. 29 Eli Lilly and Company,(NYSE: LLY ) today announced ...
... Jan. 29 /Xinhua-PRNewswire-FirstCall/ -- China Medical,Technologies, Inc. ... leading China-based,medical device company that develops, manufactures ... high intensity focused ultrasound tumor,therapy systems, today ... results for the third quarter ended December ...
... CEO Bill Novelli,made the following statement today in ... (Logo: http://www.newscom.com/cgi-bin/prnh/20070209/NYF043LOGO ), "We ... us beyond,rhetoric and towards bipartisan solutions that are ... come together, openly,debate all available options, and solve ...
Cached Medicine News:Health News:FairWarning(R) Furthers Electronic Health Record Privacy Auditing Leadership 2Health News:HealthAware Introduces Its WeightAware Cardiovascular Disease Module 2Health News:EpicTide Changes Name to FairWarning(R) 2Health News:Lilly Caps Successful Year with Strong Fourth-Quarter Results 2Health News:Lilly Caps Successful Year with Strong Fourth-Quarter Results 3Health News:Lilly Caps Successful Year with Strong Fourth-Quarter Results 4Health News:Lilly Caps Successful Year with Strong Fourth-Quarter Results 5Health News:Lilly Caps Successful Year with Strong Fourth-Quarter Results 6Health News:Lilly Caps Successful Year with Strong Fourth-Quarter Results 7Health News:Lilly Caps Successful Year with Strong Fourth-Quarter Results 8Health News:Lilly Caps Successful Year with Strong Fourth-Quarter Results 9Health News:Lilly Caps Successful Year with Strong Fourth-Quarter Results 10Health News:Lilly Caps Successful Year with Strong Fourth-Quarter Results 11Health News:Lilly Caps Successful Year with Strong Fourth-Quarter Results 12Health News:Lilly Caps Successful Year with Strong Fourth-Quarter Results 13Health News:Lilly Caps Successful Year with Strong Fourth-Quarter Results 14Health News:Lilly Caps Successful Year with Strong Fourth-Quarter Results 15Health News:Lilly Caps Successful Year with Strong Fourth-Quarter Results 16Health News:Lilly Caps Successful Year with Strong Fourth-Quarter Results 17Health News:Lilly Caps Successful Year with Strong Fourth-Quarter Results 18Health News:Lilly Caps Successful Year with Strong Fourth-Quarter Results 19Health News:Lilly Caps Successful Year with Strong Fourth-Quarter Results 20Health News:Lilly Caps Successful Year with Strong Fourth-Quarter Results 21Health News:Lilly Caps Successful Year with Strong Fourth-Quarter Results 22Health News:China Medical Technologies to Announce Financial Results for the Third Quarter Ended December 31, 2007 on February 28, 2008 2Health News:Statement by AARP CEO Bill Novelli on President Bush's State of the Union 2
The Cygnus-PFS Image-Guided Surgery System is the world's first portable and affordable image-guided surgery system....
Used for access and catheterization procedures. Double flexible tipped design permits alternative use of both ends of wire guide depending upon procedural needs. Supplied sterile in peel-open package...
The Emerald Guidewire is intended for percutaneous introduction of catheters....
Used to negotiate tortuous vessels....
Medicine Products: